Document:

Exhibit 4.24

 

THE SYMBOL “[****]” DENOTES
PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD
LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED

 

FIRST AMENDMENT TO AMENDED AND RESTATED
LICENSE AGREEMENT

 

THIS FIRST AMENDMENT
TO AMENDED AND RESTATED LICENSE AGREEMENT (this “Amendment”) is entered into effective as of the __
day of ____ 2013, by and between Tel Hashomer – Medical Research, Infrastructure
and Services Ltd. (“THM”), Ramot at Tel Aviv University Ltd. (“Ramot”) and cCAM Biotherapeutics
Ltd. (the “Company”).

 

 RECITALS:

 

WHEREAS, on April
16, 2012, the Parties entered into that certain Amended and Restated License Agreement (the “Agreement”);

 

WHEREAS, the Parties
wish to amend certain terms of the Agreement;

 

NOW, THEREFORE, the
Parties hereby agree as follows:

 

		1.	Definitions; Effectiveness of Amendment

 

1.1. Capitalized
terms used herein and not otherwise defined shall have the respective meaning ascribed to them in the Agreement.

 

1.2. Other
than as specifically amended hereby, the provisions of the Agreement shall remain in full force and effect. In the event of contradiction
between any provision of the Agreement and an amendment thereto as set forth herein, such amendment shall prevail.

 

		2.	Consideration

 

2.1. A
new sub-section 5.1.1.4 shall be added as follows:

 

“The Company shall be
entitled to offset the Milestone Payments actually paid to the Licensors pursuant to sub-section 5.1.1.3 against any amounts that
the Company is required to pay to Licensors pursuant to sub-section 5.1.1.2.1 on account of Sublicense Fees that are paid to the
Company for achievement of the same milestone for the same Biopharmaceutical Product.”.

 

2.2. The
following paragraph shall be added at the bottom of Section 5.1.4:

 

“In the event that upon
the closing of an Exit, the Company is engaged in a program for the research and development of an additional antibody, which is
not a Product (a “Program”), then, the percentage of the Exit Consideration specified in sub-sections 5.1.4(a)-(c)
shall be reduced by [****]% in connection with the first Program and by additional [****]% for each
additional Program, provided however that in any event the portion of the Exit Consideration specified in sub-sections 5.1.4(a)-(c)
shall not be less than [****]%.

 

2.3. Section
10.5 of the Agreement shall be amended such that the word “country” at the beginning of the fourth sentence from the
bottom shall be replaced with the words: “such patent application and/or patent”.

 

     

     

    

 

3. Counterparts.
This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.

 

IN WITNESS WHEREOF,
the parties hereto have executed this First Amendment to the Amended and Restated License Agreement as of the date first above
written.

 

	 	 
	CCAM BIOTHERAPEUTICS LTD.	 
	By: _________________	 
	(Name & Title of Signatory)	 

 

	 	 	 
	TEL HASHOMER – MEDICAL RESEARCH, INFRASTRACTURE AND SERVICES LTD.	 	RAMOT AT TEL AVIV UNIVERSITY LTD.
	 	 	 
	By: _________________	 	By: _________________
	(Name & Title of Signatory)	 	(Name & Title of Signatory)

 

Confirmation: 

 

I, the undersigned, Dr. Gal Markel, hereby
declare and confirm that I read and understood the foregoing, I agree to the provisions of this Amendment, and I undertake to comply
with all the conditions, provisions, instructions and stipulations of the Amendment.

 

	 	 
	Dr. Gal Markel	 

 

I, the undersigned, Dr. Jacob Schachter, hereby
declare and confirm that I read and understood the foregoing, I agree to the provisions of this Amendment, and I undertake to comply
with all the conditions, provisions, instructions and stipulations of the Amendment.

 

	 	 
	Dr. Jacob SchachterExhibit 4.25

 

SECOND
AMENDMENT TO AMENDED AND RESTATED LICENSE AGREEMENT

 

THIS
SECOND AMENDMENT TO AMENDED AND RESTATED LICENSE AGREEMENT (this “Amendment”) is entered into effective as
of the __ day of July 2015, by and between Tel Hashomer – Medical Research, Infrastructure and Services Ltd. (“THM”),
Ramot at Tel Aviv University Ltd. (“Ramot”) and cCAM Biotherapeutics Ltd. (the “Company”).

 

		1.	Definitions;
                                         Effectiveness of Amendment

 

1.1. Capitalized
terms used herein and not otherwise defined shall have the respective meaning ascribed to them in the Amended and Restated License
Agreement between THM, Ramot and the Company dated April 16, 2012, as amended (the “License Agreement”).

 

1.2. Other
than as specifically amended hereby, the provisions of the License Agreement shall remain in full force and effect. In the event
of contradiction between any provision of the License Agreement and an amendment thereto as set forth herein, such amendment shall
prevail.

 

2. Ownership
of Patent Rights. 

 

2.1. Licensors
clarifies and confirms that, as between the parties, the patent and the patent application specified in Exhibit A
and all provisional applications, counterpart application, continuations, continuations-in-part, divisions, reissues, renewals,
and patents granted thereon, all patents-of-addition, reissue patents, re-examinations and extensions or restorations by existing
or future extension or restoration mechanisms, including, without limitation, supplementary protection certificates or the equivalent
thereof, all related to the foregoing (the “Patents”) shall be deemed Company IP as such term is defined in
the License Agreement.

 

2.2. Without
derogating from the above, the Patents shall be deemed part of the Licensed Information licensed to the Company pursuant to the
License for the purpose of Section 5 of the Agreement and any consideration payable thereunder shall therefore apply to the Patents.

 

2.3. Each
of the Licensors undertakes to execute any document and take any action reasonably requested by the Company (including the execution
of letters of assignment) to perfect the title of the Company in and to said Patents.

 

3. 
Counterparts. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument.

 

IN
WITNESS WHEREOF, the parties hereto have executed this Second Amendment to the Amended and Restated License Agreement as of the
date first above written.

 

	CCAM BIOTHERAPEUTICS LTD.	 
	 	 
	By: 	                         	 
	(Name & Title of Signatory)	 

 

    

     

    

 

	TEL HASHOMER – MEDICAL RESEARCH, INFRASTRACTURE AND SERVICES LTD.	 	RAMOT AT TEL AVIV UNIVERSITY LTD.
	 	 	 
	By:  	                      	 	By:  	            
	(Name & Title of Signatory)	 	(Name & Title of Signatory)

 

Confirmation:

 

I,
the undersigned, Prof. Gal Markel, hereby declare and confirm that I read and understood the foregoing, I agree to the provisions
of this Amendment, and I undertake to comply with all the conditions, provisions, instructions and stipulations of the Amendment.

 

	 	 
	Prof.
Gal Markel	 

 

I,
the undersigned, Dr. Jacob Schachter, hereby declare and confirm that I read and understood the foregoing, I agree to the provisions
of this Amendment, and I undertake to comply with all the conditions, provisions, instructions and stipulations of the Amendment.

 

	 	 
	Dr.
Jacob Schachter	 

 

I,
the undersigned, Dr. Rona Ortenberg, hereby declare and confirm that I read and understood the foregoing, I agree to the provisions
of this Amendment, and I undertake to comply with all the conditions, provisions, instructions and stipulations of the Amendment.

 

	 	 
	Dr.
Rona Ortenberg	 

 

    

     

    

 

Exhibit
A

PatentsExhibit 4.26

 

ASSIGNMENT
AND ASSUMPTION AGREEMENT

 

Assignment
And Assumption Agreement (the “Assignment”),
made as of May  __, 2018, between cCAM Biotherapeutics Limited
(“Assignor”) and Famewave Ltd. (“Assignee”) and agreed
to by Tel Hashomer - Medical Research, Infrastructure and Services Ltd. (“Tel
Hashomer”) and Ramot at Tel Aviv University Ltd. (“Ramot”
and together with Tel Hashomner, “Licensor”).

 

W
I T N E S S E T H :

 

Whereas,
Assignor is a party to a certain Restated and Amended License Agreement dated April 16, 2012, as amended (the “Agreement”),
by and among Licensor and Assignor; and

 

Whereas,
Assignee has acquired from Assignor certain assets developed subject to the Agreement; and

 

Whereas,
Assignor and Assignee desire that Assignor assign all of Assignor’s
rights, title and interest in, to and under the Agreement to Assignee, and that Assignee assume all of Assignor’s obligations
and duties under the Agreement; and

 

Whereas,
Licensor is willing to consent to such assignment and assumption
on the terms and subject to the conditions set forth herein;

 

Now,
Therefore, in consideration of the mutual
covenants and conditions hereinafter set forth, the parties hereto agree as follows:

 

ARTICLE
I

ASSIGNMENT
OF RIGHTS; ASSUMPTION OF OBLIGATIONS

 

Section
1.1. Assignor hereby acknowledges that it has assigned to Assignee all of its rights, title and interest under the Agreement
and Assignee has accepted such assignment.

 

Section
1.2. Assignee hereby assumes and agrees to undertake and perform any and all obligations and duties of Assignor under the
Agreement.

 

ARTICLE
II

LICENSOR’S
CONSENT

 

Section
2.1. Licensor hereby consents and agrees to the assignment and assumption set forth in Article I hereof.

 

    

     

    

 

ARTICLE
III

MISCELLANEOUS

 

Section
3.1. Counterparts. This Assignment may be executed in multiple copies, each of which shall for all purposes bind the
parties, and each party hereby covenants and agrees to execute all duplicates or replacement counterparts of this Assignment as
may be required.

 

Section
3.2. Applicable Law. This Assignment shall be governed by and construed in accordance with the laws of the State of
New York, without giving effect to the conflicts of laws provisions thereof.

 

In
Witness Whereof, the parties have caused
this Assignment to be executed by their authorized officers as of the date first written above.

 

	cCAM
    Biotherapeutics Limited	 	Famewave
    Ltd.
	 	 	 
	By: 	                         	 	By: 	            
	 	Name:	 	 	Name:
	 	Title:	 	 	Title:
	 	 	 
	Tel
    Hashomer - Medical Research, Infrastructure and Services Ltd.	 	Ramot
    at Tel Aviv University Ltd.
	 	 	 
	By: 	          	 	By: 	         
	 	Name:	 	 	Name:
	 	Title:	 	 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}]]